|
GSK gets good news on asthma drug
Triangle Business Journal GlaxoSmithKline (NYSE: GSK) announced statistically significant Phase 3 results for Relovair, an asthma treatment that the British drug giant is developing with partner Theravance Inc. (NASDAQ: THRX). Relovair is a once-daily inhaled treatment for … Glaxo Drug Gets Positive Trial Results Theravance, Glaxo Lung Drug Passes Two Pivotal Trials; Two More to Go Glaxo reports positive results for inhaler drug |
View full post on asthma – Google News